Summary of minutes of EUCAST Steering Committee Meeting
Madrid, Spain, 29-30 January 2007

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Canton RC Clinical Data Co-ordinator Spain
Dr Christian Giske CG SRGA Sweden
Dr Fred Goldstein FG SFM France
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Arne Rodloff AR DIN Germany
Dr Martin Steinbakk MS NWGA Norway
Prof Pietro Varaldo PV EUCAST Italy

Apologies
Prof Waleria Hryniewicz WH EUCAST Poland
Prof Inga Odenholt IO SRGA Sweden

In attendance for item 13
Dr J. Peter Donnelly PD University Medical Centre St Radboud, Nijmegen, The Netherlands
Dr Juan-Luis Rodriguez-Tudela JR National Center for Microbiology, Majadahonda, Spain
Dr Manuel Cuenca-Estrella ME National Center for Microbiology, Majadahonda, Spain
Dr Cornelia Lass-Flörl CF Division of Hygiene and Microbiology, Innesbruck Medical University, Austria
Dr Maiken Cavling Arendrup MA Statens Serum Institut, Copenhagen, Denmark

1 Chairman’s welcome

2 Minutes of meeting of 20-21 November 2006 With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of 20-21 November 2006
Content of the clinical data section for older agents was agreed.
Most declarations of interest have been returned.
For S. pneumoniae with piperacillin-tazobactam susceptibility should be inferred from the penicillin susceptibility.
Developments of the wild type website are in progress.
Documents related to new quinolone breakpoints have been updated.
Technical notes and rationale documents for aminoglycosides, carbapenems, glycopeptides, penicillins, fluoroquinolones, fluconazole, macrolides and miscellaneous agents are progressing and are at various stages of development.
For trimethoprim with enterococci evidence on clinical validity is not available.

4 CLSI
Relationships between CLSI and FDA are still to be clarified.
Penicillin breakpoints for pneumococci will be reviewed at the meeting in June and revised CLSI cephalosporin breakpoints for Enterobacteriaceae will be developed.

5 Ciprofloxacin rationale document
The document was update as a model for others.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>6</strong></td>
<td><strong>New glycopeptide</strong>&lt;br&gt;A preliminary presentation was given by the company.</td>
</tr>
<tr>
<td><strong>7</strong></td>
<td><strong>New quinolone</strong>&lt;br&gt;The company response to EUCAST proposals was reviewed.</td>
</tr>
<tr>
<td><strong>8</strong></td>
<td><strong>New quinolone meeting with the company</strong>&lt;br&gt;The company response to EUCAST proposals was discussed and breakpoints finalised.</td>
</tr>
<tr>
<td><strong>9</strong></td>
<td><strong>Miscellaneous agents</strong>&lt;br&gt;Dosage and current breakpoint data were updated.</td>
</tr>
<tr>
<td><strong>10</strong></td>
<td><strong>Expert rules sub-committee</strong>&lt;br&gt;The first draft was now completed and will be sent to National Committees for comment.</td>
</tr>
<tr>
<td><strong>11</strong></td>
<td><strong>EMEA</strong>&lt;br&gt;Proposed changes to the EMEA-EUCAST SOP were agreed.</td>
</tr>
<tr>
<td><strong>12</strong></td>
<td><strong>New drugs</strong>&lt;br&gt;Current status was reviewed.</td>
</tr>
<tr>
<td><strong>13</strong></td>
<td><strong>Joint meeting with the AFST subcommittee</strong>&lt;br&gt;Proposals for future activity were discussed. Problems with different methodologies were highlighted. The fluconazole rationale document was reviewed.</td>
</tr>
<tr>
<td><strong>14</strong></td>
<td><strong>Macrolides</strong>&lt;br&gt;Draft breakpoints were reviewed and updated. The breakpoints will be sent for wider consultation.</td>
</tr>
<tr>
<td><strong>15</strong></td>
<td><strong>ISO/CEN</strong>&lt;br&gt;The document on assessment of in-vitro methods is about to go for final voting.</td>
</tr>
<tr>
<td><strong>16</strong></td>
<td><strong>Miscellaneous agents</strong>&lt;br&gt;National data have been tabulated. Breakpoints will be discussed at the next meeting.</td>
</tr>
<tr>
<td><strong>17</strong></td>
<td><strong>Penicillins</strong>&lt;br&gt;Draft breakpoints were reviewed and updated. The breakpoints will be sent for wider consultation.</td>
</tr>
<tr>
<td><strong>18</strong></td>
<td><strong>Any other business</strong>&lt;br&gt;Implementation of EUCAST breakpoints in disc diffusion methods is done for BSAC, SRGA and SFM methods.</td>
</tr>
<tr>
<td><strong>19</strong></td>
<td><strong>Next meetings</strong>&lt;br&gt;3-4 April 2007, Munich; 14-15 June 2007, Copenhagen; 6-7 September 2007, Berlin; 19-20 November 2007, Paris</td>
</tr>
</tbody>
</table>